Multiple myeloma: therapeutic delivery of antibodies and aptamers

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Kumar SK, Rajkumar V, Kyle RA et al. Multiple myeloma. Nat. Rev. Dis. Primers 3(1), 17046 (2017). •• Provides background to multiple myeloma and should be read to give context to the whole paper. Gives an overview of the disease and a range of drugs used.
  MedlineGoogle Scholar
• 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 66(1), 7–30 (2016).
  MedlineGoogle Scholar
• 3. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol. 95(5), 548–567 (2020).
  Medline CASGoogle Scholar
• 4. Gonsalves WI, Gertz MA, Gupta V et al. Prognostic significance of quantifying circulating plasma cells in multiple myeloma. Clin. Lymphoma Myeloma Leuk. 14, S147 (2014).
  Google Scholar
• 5. Blade J, De Larrea CF, Rosinol L. Extramedullary involvement in multiple myeloma. Haematologica 97(11), 1618–1619 (2012).
  MedlineGoogle Scholar
• 6. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97(9), 2900–2902 (2001).
  Medline CASGoogle Scholar
• 7. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78(1), 21–33 (2003).
  MedlineGoogle Scholar
• 8. Rajkumar SV, Dimopoulos MA, Palumbo A et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15(12), e538–e548 (2014).
  MedlineGoogle Scholar
• 9. Dhodapkar MV. MGUS to myeloma: a mysterious gammopathy of underexplored significance. Blood 128(23), 2599–2606 (2016).
  Medline CASGoogle Scholar
• 10. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113(22), 5418–5422 (2009).
  Medline CASGoogle Scholar
• 11. Turesson I, Kovalchik SA, Pfeiffer RM et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 123(3), 338–345 (2014).
  Medline CASGoogle Scholar
• 12. Dispenzieri A, Kyle RA, Katzmann JA et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111(2), 785–789 (2008).
  Medline CASGoogle Scholar
• 13. Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
  MedlineGoogle Scholar
• 14. Huang Y-F, Lin Y-W, Lin Z-H, Chang H-T. Aptamer-modified gold nanoparticles for targeting breast cancer cells through light scattering. J. Nanopart. Res. 11(4), 775–783 (2009).
  CASGoogle Scholar
• 15. Waxman AJ, Mink PJ, Devesa SS et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116(25), 5501–5506 (2010).
  Medline CASGoogle Scholar
• 16. Dimopoulos MA, Moreau P, Terpos E et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 32(3), 309–322 (2021).
  Medline CASGoogle Scholar
• 17. Myeloma UK. Daratumumab (Darzalex^®) is accepted for use within NHS Scotland (2021). https://www.myeloma.org.uk/news/daratumumab-approved-for-use-on-nhs-in-scotland/
  Google Scholar
• 18. Attal M, Lauwers-Cances V, Marit G et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 366(19), 1782–1791 (2012).
  Medline CASGoogle Scholar
• 19. Mccarthy PL, Holstein SA, Petrucci MT et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J. Clin. Oncol. 35(29), 3279–3289 (2017).
  Medline CASGoogle Scholar
• 20. Kumar SK, Mikhael JR, Buadi FK et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin. Proc. 84(12), 1095–1110 (2009).
  Medline CASGoogle Scholar
• 21. Rajan AM, Rajkumar SV. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J. 5(10), e365–e365 (2015).
  Medline CASGoogle Scholar
• 22. Vu T, Gonsalves W, Kumar S et al. Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. Blood Cancer J. 5(10), e363–e363 (2015).
  Medline CASGoogle Scholar
• 23. Neben K, Lokhorst HM, Jauch A et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119(4), 940–948 (2012).
  Medline CASGoogle Scholar
• 24. Kumar SK, Lee JH, Lahuerta JJ et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26(1), 149–157 (2012).
  Medline CASGoogle Scholar
• 25. King AJ, Eyre T, Sharpley F, Watson C, Ramasamy K, Willan J. Multiple myeloma in the very elderly patient: challenges and solutions. Clin. Interv. Aging 2016, 423–435 (2016).
  Google Scholar
• 26. Reghunathan R, Bi C, Liu SC et al. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget 4(8), 1230–1240 (2013).
  MedlineGoogle Scholar
• 27. Morita Y, Leslie M, Kameyama H, Volk D, Tanaka T. Aptamer therapeutics in cancer: current and future. Cancers (Basel) 10(3), 80 (2018). •• Background to aptamer therapeutics and essential reading for a background into aptamers – gives the advantages and challenges faced with aptamer use in oncology.
  Google Scholar
• 28. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother. 58(3), 317–324 (2009).
  MedlineGoogle Scholar
• 29. Pisetsky DS. Anti-DNA antibodies — quintessential biomarkers of SLE. Nat. Rev. Rheumatol. 12(2), 102–110 (2016).
  Medline CASGoogle Scholar
• 30. Sela-Culang I, Kunik V, Ofran Y. The structural basis of antibody-antigen recognition. Front. Immunol. 4, 302 (2013).
  MedlineGoogle Scholar
• 31. Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol. Immunol. 67(2), 171–182 (2015).
  Medline CASGoogle Scholar
• 32. Lonial S, Dimopoulos M, Palumbo A et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373(7), 621–631 (2015).
  Medline CASGoogle Scholar
• 33. Dimopoulos MA, Dytfeld D, Grosicki S et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 379(19), 1811–1822 (2018).
  Medline CASGoogle Scholar
• 34. Attal M, Richardson PG, Rajkumar SV et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, Phase III study. Lancet 394(10214), 2096–2107 (2019).
  Medline CASGoogle Scholar
• 35. Moreau P, Dimopoulos M-A, Mikhael J et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised Phase III trial. Lancet 397(10292), 2361–2371 (2021).
  Medline CASGoogle Scholar
• 36. Spencer A, Lentzsch S, Weisel K et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 103(12), 2079–2087 (2018).
  Medline CASGoogle Scholar
• 37. Dimopoulos MA, Oriol A, Nahi H et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(14), 1319–1331 (2016).
  Medline CASGoogle Scholar
• 38. Hsi ED, Steinle R, Balasa B et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14(9), 2775–2784 (2008).
  Medline CASGoogle Scholar
• 39. Tai Y-T, Dillon M, Song W et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112(4), 1329–1337 (2008).
  Medline CASGoogle Scholar
• 40. Martin TG, Hsu K, Charpentier E et al. A Phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. J. Clin. Oncol. 32(Suppl. 15), 8512–8512 (2014).
  Google Scholar
• 41. De Weers M, Tai Y-T, Van Der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186(3), 1840–1848 (2011).
  MedlineGoogle Scholar
• 42. Lokhorst HM, Plesner T, Gimsing P et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 31(Suppl. 15), 8512–8512 (2013).
  Google Scholar
• 43. Raab MS, Engelhardt M, Blank A et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial. Lancet Haematol. 7(5), e381–e394 (2020).
  MedlineGoogle Scholar
• 44. Kumar SK, Cornell RF, Landgren O et al. A Phase I first-in-human study of the anti-CD38 dimeric fusion protein TAK-169 for the treatment of patients (pts) with relapsed or refractory multiple myeloma (RRMM) who are proteasome inhibitor (PI)- and immunomodulatory drug (IMiD)-refractory, including Pts relapsed/refractory (R/R) or naïve to daratumumab (dara). Blood 134(Suppl. 1), 1867–1867 (2019).
  Google Scholar
• 45. Zojer N, Kirchbacher K, Vesely M, Hübl W, Ludwig H. Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma. Leuk. Lymphoma 47(6), 1103–1109 (2006).
  Medline CASGoogle Scholar
• 46. Hussein M, Berenson JR, Niesvizky R et al. A Phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95(5), 845–848 (2010).
  Medline CASGoogle Scholar
• 47. Ailawadhi S, Kelly KR, Vescio RA et al. A Phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD–56-positive multiple myeloma. Clin Lymphoma Myeloma Leuk. 19(1), 29–34 (2019).
  MedlineGoogle Scholar
• 48. Mcearchern JA, Smith LM, Mcdonagh CF et al. Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin. Cancer Res. 14(23), 7763–7772 (2008).
  Medline CASGoogle Scholar
• 49. Mahadevan D, Lanasa MC, Farber C et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J. Immunother. Cancer. 7(1), 1–13 (2019).
  MedlineGoogle Scholar
• 50. Tai Y-T, Muchhal U, Li X-F et al. XmAb^®5592 Fc-engineered humanized anti-HM1.24 monoclonal antibody has potent in vitro and in vivo efficacy against multiple myeloma. Blood 114(22), 609–609 (2009).
  Google Scholar
• 51. Baz RC, Zonder JA, Gasparetto C, Reu FJ, Strout V. Phase I study of anti-GM2 ganglioside monoclonal antibody BIW-8962 as monotherapy in patients with previously treated multiple myeloma. Oncol. Ther. 4(2), 287–301 (2016).
  MedlineGoogle Scholar
• 52. Moreau P, Cavallo F, Leleu X et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 25(5), 872–874 (2011).
  Medline CASGoogle Scholar
• 53. Atzori F, Tabernero J, Cervantes A et al. A Phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 17(19), 6304–6312 (2011).
  Medline CASGoogle Scholar
• 54. Zagouri F, Terpos E, Kastritis E, Dimopoulos MA. Emerging antibodies for the treatment of multiple myeloma. Expert Opin Emerg Drugs. 21(2), 225–237 (2016).
  Medline CASGoogle Scholar
• 55. Benson DM, Cohen AD, Jagannath S et al. A Phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin. Cancer Res. 21(18), 4055–4061 (2015).
  Medline CASGoogle Scholar
• 56. Vey N, Karlin L, Sadot-Lebouvier S et al. A Phase I study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget 9(25), 17675–17688 (2018).
  MedlineGoogle Scholar
• 57. Carlo-Stella C, Guidetti A, Di Nicola M et al. IFN-γ enhances the antimyeloma activity of the fully human anti–human leukocyte antigen-DR monoclonal antibody 1D09C3. Cancer Res. 67(7), 3269–3275 (2007).
  Medline CASGoogle Scholar
• 58. Belch A, Sharma A, Spencer A et al. A multicenter randomized Phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with bortezomib in patients with relapsed/refractory multiple myeloma (MM). Blood 116(21), 5031–5031 (2010).
  Google Scholar
• 59. Brighton TA, Khot A, Harrison SJ et al. Randomized, double-blind, placebo-controlled, multicenter study of siltuximab in high-risk smoldering multiple myeloma. Clin. Cancer Res. 25(13), 3772–3775 (2019).
  Medline CASGoogle Scholar
• 60. Rossi JF, Fegueux N, Lu ZY et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m² of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant. 36(9), 771–779 (2005).
  Medline CASGoogle Scholar
• 61. Matsuyama Y, Nagashima T, Honne K et al. Successful treatment of a patient with rheumatoid arthritis and IgA-kappa multiple myeloma with tocilizumab. Intern. Med. 50(6), 639–642 (2011).
  Medline CASGoogle Scholar
• 62. White D, Kassim A, Bhaskar B, Yi J, Wamstad K, Paton VE. Results from AMBER, a randomized Phase II study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 119(2), 339–347 (2013).
  Medline CASGoogle Scholar
• 63. Trudel S, Stewart AK, Rom E et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 107(10), 4039–4046 (2006).
  Medline CASGoogle Scholar
• 64. Kamath AV, Lu D, Gupta P et al. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma. Cancer Chemother. Pharmacol. 69(4), 1071–1078 (2012).
  Medline CASGoogle Scholar
• 65. Vij R, Horvath N, Spencer A et al. An open-label, Phase II trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am. J. Hematol. 84(10), 650–656 (2009).
  Medline CASGoogle Scholar
• 66. Fulciniti M, Tassone P, Hideshima T et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114(2), 371–379 (2009).
  Medline CASGoogle Scholar
• 67. Abdulkadyrov KM, Salogub GN, Khuazheva NK et al. ACE-011, a soluble activin receptor type IIa IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis. Blood 114(22), 749–749 (2009).
  MedlineGoogle Scholar
• 68. Wichert S, Juliusson G, Johansson Å et al. A single-arm, open-label, Phase II clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma. PLoS ONE 12(2), e0171205 (2017).
  MedlineGoogle Scholar
• 69. Raje NS, Moreau P, Terpos E et al. Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. Br. J. Haematol. 176(5), 783–795 (2017).
  Medline CASGoogle Scholar
• 70. Dulos J, Lilian D, Snippert M et al. Bion-1301: a novel fully blocking APRIL antibody for the treatment of multiple myeloma. Blood 128(22), 2112–2112 (2016).
  MedlineGoogle Scholar
• 71. Ghobrial IM, Liu C-J, Redd RA et al. A Phase Ib/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma. Clin. Cancer Res. 26(2), 344–353 (2020).
  Medline CASGoogle Scholar
• 72. Ochoa MC, Perez-Ruiz E, Minute L et al. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells. Oncoimmunology 8(7), e1599636 (2019).
  MedlineGoogle Scholar
• 73. Mcdonald MM, Reagan MR, Youlten SE et al. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood 129(26), 3452–3464 (2017).
  Medline CASGoogle Scholar
• 74. Toscani D, Bolzoni M, Ferretti M, Palumbo C, Giuliani N. Role of osteocytes in myeloma bone disease: anti-sclerostin antibody as new therapeutic strategy. Front. Immunol. 9, 2467 (2018).
  MedlineGoogle Scholar
• 75. Pianko MJ, Funt SA, Page DB et al. Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma. Leuk. Lymphoma 59(1), 221–224 (2018).
  Medline CASGoogle Scholar
• 76. Jelinek T, Paiva B, Hajek R. Update on PD-1/PD-L1 inhibitors in multiple myeloma. Front. Immunol. 9, 2431 (2018).
  MedlineGoogle Scholar
• 77. Von Tresckow B, Boell B, Eichenauer D et al. Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial. Leuk. Lymphoma 55(3), 695–697 (2014).
  MedlineGoogle Scholar
• 78. Nejadmoghaddam M-R, Minai-Tehrani A, Ghahremanzadeh R, Mahmoudi M, Dinarvand R, Zarnani A-H. Antibody-drug conjugates: possibilities and challenges. Avicenna J. Med. Biotechnol. 11(1), 3–23 (2019).
  MedlineGoogle Scholar
• 79. Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J. Natl Cancer Inst. 111(6), 538–549 (2019). •• Describes the concept of antibody–drug conjugate-based therapeutics – examples of four therapeutics detailed.
  MedlineGoogle Scholar
• 80. Ikeda H, Hideshima T, Fulciniti M et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15(12), 4028–4037 (2009).
  Medline CASGoogle Scholar
• 81. Kaufman JL, Niesvizky R, Stadtmauer EA et al. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma. Br. J. Haematol. 163(4), 478–486 (2013).
  Medline CASGoogle Scholar
• 82. Abrahams CL, Li X, Embry M et al. Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001. Oncotarget 9(102), 37700–37714 (2018).
  MedlineGoogle Scholar
• 83. Krishnan L, Sahni G, Kaur KJ, Salunke DM. Role of antibody paratope conformational flexibility in the manifestation of molecular mimicry. Biophys. J. 94(4), 1367–1376 (2008).
  Medline CASGoogle Scholar
• 84. Lebovic D, Kaminski MS, Anderson TB et al. A Phase II study of consolidation treatment with Iodione-131 tositumomab (Bexxar™) in multiple myeloma (MM). Blood 120(21), 1854–1854 (2012).
  Google Scholar
• 85. Chanan-Khan A, Wolf J, Gharibo M et al. Phase I study of IMGN901, used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma - a preliminary safety and efficacy analysis. Blood 114(22), 2883–2883 (2009).
  Google Scholar
• 86. Fatholahi M, Valencia M, Mark A et al. TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo. Clin. Lymphoma Myeloma Leuk. 19(10), e116 (2019).
  MedlineGoogle Scholar
• 87. Doronina SO, Toki BE, Torgov MY et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21(7), 778–784 (2003).
  Medline CASGoogle Scholar
• 88. Lewis TS, Olson D, Gordon K et al. SGN-CD48A: a novel humanized anti-CD48 antibody-drug conjugate for the treatment of multiple myeloma. Blood 128(22), 4470–4470 (2016).
  Google Scholar
• 89. Rhode PR, Egan JO, Xu W et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 4(1), 49–60 (2016).
  Medline CASGoogle Scholar
• 90. Markham A. Belantamab mafodotin: first approval. Drugs 80(15), 1607–1613 (2020).
  Medline CASGoogle Scholar
• 91. Kinneer K, Meekin J, Varkey R et al. Preclinical evaluation of MEDI2228, a BCMA-targeting pyrrolobenzodiazepine-linked antibody drug conjugate for the treatment of multiple myeloma. Blood 130(Suppl. 1), 3153–3153 (2017).
  Google Scholar
• 92. Lee HC, Raje NS, Landgren O et al. Phase I study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. Leukemia 35(1), 255–258 (2021).
  Medline CASGoogle Scholar
• 93. Singh RK, Jones RJ, Shirazi F et al. HDP-101, a novel BCMA-targeted antibody conjugated to α-amanitin, is active against myeloma with preferential efficacy against pre-clinical models of deletion 17p. Clin. Lymphoma Myeloma Leuk. 19(10), e152 (2019).
  Google Scholar
• 94. Linderoth E, Helke S, Lee V et al. Abstract 2653: the anti-myeloma activity of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor. Cancer Res. 77(Suppl. 13), 2653–2653 (2017).
  Google Scholar
• 95. Levy MY, Cicic D, Bergonio G, Berger M. Trial in progress: Phase I study of actinium-225 (225Ac)-lintuzumab in patients with refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 17, S329–S330 (2017).
  MedlineGoogle Scholar
• 96. Stewart AK, Krishnan AY, Singhal S et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J. 9(2), (2019).
  Google Scholar
• 97. Slaney CY, Wang P, Darcy PK, Kershaw MH. CARs versus BiTEs: a comparison between T cell–redirection strategies for cancer treatment. Cancer Discov. 8(8), 924–934 (2018).
  Medline CASGoogle Scholar
• 98. Girgis S, Shetty S, Jiao T et al. Exploratory pharmacokinetic/pharmacodynamic and tolerability study of BCMAxCD3 in cynomolgus monkeys. Blood 128(22), 5668–5668 (2016).
  Google Scholar
• 99. Li J, Stagg NJ, Johnston J et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5/CD3 and is a requirement for myeloma cell killing. Cancer Cell 31(3), 383–395 (2017).
  Medline CASGoogle Scholar
• 100. Topp MS, Duell J, Zugmaier G et al. Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: updated results of a first-in-human (FIH) Phase I dose escalation study. J. Clin. Oncol. 37(Suppl. 15), 8007–8007 (2019).
  Google Scholar
• 101. Seckinger A, Delgado JA, Moser S et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody em801 for multiple myeloma treatment. Cancer Cell 31(3), 396–410 (2017).
  Medline CASGoogle Scholar
• 102. Bahlis NJ, Raje NS, Costello C et al. Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM). J. Clin. Oncol. 39(Suppl. 15), 8006–8006 (2021).
  Google Scholar
• 103. Moreno L, Zabaleta A, Alignani D et al. New insights into the mechanism of action (MoA) of first-in-class IgG-based BCMA T-cell bispecific antibody (TCB) for the treatment of multiple myeloma (MM). Blood 128(22), 2096–2096 (2016).
  MedlineGoogle Scholar
• 104. Buelow B, Choudry P, Clarke S et al. Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma. J. Clin. Oncol. 36(Suppl. 15), 8034–8034 (2018).
  Google Scholar
• 105. Gantke T, Weichel M, Herbrecht C et al. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Eng. Des. Sel. 30(9), 673–684 (2017).
  Medline CASGoogle Scholar
• 106. Cohen AD, Trudel S, Forsberg PA et al. GO39775: a multicenter Phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 38(Suppl. 15), TPS8551–TPS8551 (2020).
  Google Scholar
• 107. Zou J, Chen D, Zong Y et al. Immunotherapy based on bispecific T-cell engager with hIgG 1 Fc sequence as a new therapeutic strategy in multiple myeloma. Cancer Sci. 106(5), 512–521 (2015).
  Medline CASGoogle Scholar
• 108. Chen D, Zou J, Zong Y, Meng H, An G, Yang L. Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization. Immunopharmacol. Immunotoxicol. 38(3), 175–183 (2016).
  Medline CASGoogle Scholar
• 109. Chan WK, Kang S, Youssef Y et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunol. Res. 6(7), 776–787 (2018).
  Medline CASGoogle Scholar
• 110. Ramadoss NS, Schulman AD, Choi SH et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. J. Am. Chem. Soc. 137(16), 5288–5291 (2015).
  Medline CASGoogle Scholar
• 111. Soldevilla M, Meraviglia-Crivelli De Caso D, Menon A, Pastor F. Aptamer-iRNAs as therapeutics for cancer treatment. Pharmaceuticals 11(4), 108 (2018).
  CASGoogle Scholar
• 112. Mignani S, Shi X, Ceña V, Majoral J-P. Dendrimer– and polymeric nanoparticle–aptamer bioconjugates as nonviral delivery systems: a new approach in medicine. Drug Discov. Today 25(6), 1065–1073 (2020).
  Medline CASGoogle Scholar
• 113. Stewart M. Extended duration vascular endothelial growth factor inhibition in the eye: failures, successes, and future possibilities. Pharmaceutics 10(1), 21 (2018).
  Google Scholar
• 114. Ludwig H, Weisel K, Petrucci MT et al. Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. Leukemia 31(4), 997–1000 (2017).
  Medline CASGoogle Scholar
• 115. Hori S-I, Herrera A, Rossi J, Zhou J. Current advances in aptamers for cancer diagnosis and therapy. Cancers (Basel) 10(1), 9 (2018).
  Google Scholar
• 116. Fu Z, Xiang J. Aptamers, the nucleic acid antibodies, in cancer therapy. Int. J. Mol. Sci. 21(8), 2793 (2020). •• An important read to understnd how aptamers are produced and their application in oncology.
  CASGoogle Scholar
• 117. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol. Cancer Ther. 5(12), 2957–2962 (2006).
  Medline CASGoogle Scholar
• 118. Vater A, Sahlmann J, Kröger N et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin. Pharmacol. Ther. 94(1), 150–157 (2013).
  Medline CASGoogle Scholar
• 119. Heo K, Min S-W, Sung HJ et al. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. J. Control. Rel. 229, 1–9 (2016).
  Medline CASGoogle Scholar
• 120. Kim HJ, Sung HJ, Lee YM et al. Therapeutic application of drug-conjugated HER2 Oligobody (HER2-DOligobody). Int. J. Mol. Sci. 21(9), 3286 (2020).
  CASGoogle Scholar
• 121. Kim M, Kim D-M, Kim K-S, Jung W, Kim D-E. Applications of cancer cell-specific aptamers in targeted delivery of anticancer therapeutic agents. Molecules 23(4), 830 (2018).
  Google Scholar
• 122. Adachi T, Nakamura Y. Aptamers: a review of their chemical properties and modifications for therapeutic application. Molecules 24 ( 23),4229 (.2019).
  CASGoogle Scholar
• 123. Kuntz ID, Blaney JM, Oatley SJ, Langridge R, Ferrin TE. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 161(2), 269–288 (1982).
  Medline CASGoogle Scholar
• 124. Recanatini M. How dynamic docking simulations can help to tackle tough drug targets. Future Med. Chem. 10(24), 2763–2765 (2018).
  CASGoogle Scholar
• 125. Taylor RD, Jewsbury PJ, Essex JW. A review of protein-small molecule docking methods. J. Comput. Aided Mol. Des. 16(3), 151–166 (2002).
  Medline CASGoogle Scholar
• 126. Gervasio FL, Laio A, Parrinello M. Flexible docking in solution using metadynamics. J. Am. Chem. Soc. 127(8), 2600–2607 (2005).
  Medline CASGoogle Scholar
• 127. De Vivo M, Masetti M, Bottegoni G, Cavalli A. Role of molecular dynamics and related methods in drug discovery. J. Med. Chem. 59(9), 4035–4061 (2016).
  MedlineGoogle Scholar
• 128. Ferruz N, Doerr S, Vanase-Frawley MA et al. Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs. Sci. Rep. 8(1), (2018).
  MedlineGoogle Scholar
• 129. Rougé L, Chiang N, Steffek M et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science 367(6483), 1224–1230 (2020).
  Medline CASGoogle Scholar
• 130. Kubiak-Ossowska K, Jachimska B, Al Qaraghuli M, Mulheran PA. Protein interactions with negatively charged inorganic surfaces. Curr. Opin. Colloid. Interface Sci. 41, 104–117 (2019). • Example of molecular dynamics simulations in two model proteins.
  CASGoogle Scholar
• 131. Al Qaraghuli M, Kubiak-Ossowska K, Mulheran P. Thinking outside the laboratory: analyses of antibody structure and dynamics within different solvent environments in molecular dynamics (MD) Simulations. Antibodies 7(3), 21 (2018). • Example of the use of molecular dynamics simulations to study antibodies.
  Google Scholar
• 132. Cardoso MM, Peca IN, Roque CAA. Antibody-conjugated nanoparticles for therapeutic applications. Curr. Med. Chem. 19(19), 3103–3127 (2012). •• Comprehensive review of antibody-based nanoparticle therapeutics.
  Medline CASGoogle Scholar
• 133. Huang Y-H, Vakili M, Molavi O et al. Decoration of anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma. Cancers (Basel) 11(2), 248 (2019).
  CASGoogle Scholar
• 134. Detappe A, Reidy M, Yu Y et al. Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. Nanoscale 11(43), 20485–20496 (2019).
  Medline CASGoogle Scholar
• 135. Zheleznyak A, Shokeen M, Achilefu S. Nanotherapeutics for multiple myeloma. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 10(6), e1526 (2018).
  MedlineGoogle Scholar
• 136. Tran S, Degiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin. Transl. Med. 6(1), 44 (2017).
  MedlineGoogle Scholar
• 137. Shi F, Li M, Wang J et al. Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles. Stem Cell. Res. Ther. 9(1), 1–11 (2018).
  MedlineGoogle Scholar
• 138. Yang C, Xiong F, Dou J et al. Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model. Oncotarget 6(29), 27714–27724 (2015).
  MedlineGoogle Scholar
• 139. Liang H, Zhang X-B, Lv Y et al. Functional DNA-containing nanomaterials: cellular applications in biosensing, imaging, and targeted therapy. Acc. Chem. Res. 47(6), 1891–1901 (2014).
  Medline CASGoogle Scholar
• 140. Park H, Kim D-M, Baek SE, Kim K-S, Kim D-E. Comparison of drug delivery efficiency between doxorubicin intercalated in RNA aptamer and one encapsulated in RNA aptamer-conjugated liposome. Bull. Korean Chem. Soc. 36(10), 2494–2500 (2015).
  CASGoogle Scholar
• 141. Alshaer W, Hillaireau H, Vergnaud J et al. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J. Control. Rel. 271, 98–106 (2018).
  Medline CASGoogle Scholar
• 142. Moosavian SA, Abnous K, Akhtari J, Arabi L, Gholamzade Dewin A, Jafari M. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells. Artif. Cells Nanomed. Biotechnol. 46, 2054–2065 (2017).
  MedlineGoogle Scholar
• 143. Xing H, Tang L, Yang X et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J. Mater. Chem. B. 1(39), 5288 (2013).
  Medline CASGoogle Scholar
• 144. Aravind A, Jeyamohan P, Nair R et al. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol. Bioeng. 109(11), 2920–2931 (2012).
  Medline CASGoogle Scholar
• 145. Chen Z, Tai Z, Gu F, Hu C, Zhu Q, Gao S. Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy. Eur. J. Pharm. Biopharm. 107, 130–141 (2016).
  Medline CASGoogle Scholar
• 146. Farokhzad OC, Cheng J, Teply BA et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA. 103(16), 6315–6320 (2006).
  Medline CASGoogle Scholar
• 147. Majidi Zolbanin N, Jafari R, Majidi J et al. Targeted co-delivery of docetaxel and cMET siRNA for treatment of Mucin1 overexpressing breast cancer cells. Adv. Pharm. Bull. 8(3), 383–393 (2018).
  MedlineGoogle Scholar
• 148. Taghavi S, Nia AH, Abnous K, Ramezani M. Polyethylenimine-functionalized carbon nanotubes tagged with AS1411 aptamer for combination gene and drug delivery into human gastric cancer cells. Int. J. Pharm. 516(1–2), 301–312 (2017).
  Medline CASGoogle Scholar
• 149. Wang K, Yao H, Meng Y, Wang Y, Yan X, Huang R. Specific aptamer-conjugated mesoporous silica–carbon nanoparticles for HER2-targeted chemo-photothermal combined therapy. Acta Biomater. 16, 196–205 (2015).
  Medline CASGoogle Scholar
• 150. Xie X, Li F, Zhang H et al. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery. Eur. J. Pharm. Sci. 83, 28–35 (2016).
  Medline CASGoogle Scholar
• 151. Ayatollahi S, Salmasi Z, Hashemi M et al. Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells. Int. J. Biochem. Cell Biol. 92, 210–217 (2017).
  Medline CASGoogle Scholar
• 152. Xu W, Siddiqui IA, Nihal M et al. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 34(21), 5244–5253 (2013).
  Medline CASGoogle Scholar
• 153. Cohen BA, Bergkvist M. Targeted in vitro photodynamic therapy via aptamer-labeled, porphyrin-loaded virus capsids. J. Photochem. Photobiol. B: Biol. 121, 67–74 (2013).
  Medline CASGoogle Scholar
• 154. Kang H, Trondoli AC, Zhu G et al. Near-infrared light-responsive core–shell nanogels for targeted drug delivery. ACS Nano 5(6), 5094–5099 (2011).
  Medline CASGoogle Scholar
• 155. Wedekind MF, Denton NL, Chen C-Y, Cripe TP. Pediatric cancer immunotherapy: opportunities and challenges. Pediatric Drugs 20(5), 395–408 (2018).
  MedlineGoogle Scholar
• 156. Reck M, Rodríguez-Abreu D, Robinson AG et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016).
  Medline CASGoogle Scholar
• 157. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9(7), 537–550 (2010).
  Medline CASGoogle Scholar
• 158. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol. Ther. Nucleic Acids. 3(8), e182–e182 (2014).
  Medline CASGoogle Scholar
• 159. Ye M, Hu J, Peng M et al. Generating aptamers by cell-SELEX for applications in molecular medicine. Int. J. Mol. Sci. 13(3), 3341–3353 (2012).
  Medline CASGoogle Scholar
• 160. Esposito C, Catuogno S, Condorelli G, Ungaro P, De Franciscis V. Aptamer chimeras for therapeutic delivery: the challenging perspectives. Genes 9(11), 529 (2018).
  Google Scholar
• 161. Sun H, Zu Y. Aptamers and their applications in nanomedicine. Small 11(20), 2352–2364 (2015).
  Medline CASGoogle Scholar
• 162. Parekh P, Kamble S, Zhao N, Zeng Z, Portier BP, Zu Y. Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials 34(35), 8909–8917 (2013).
  Medline CASGoogle Scholar
• 163. Rosenberg JE, Bambury RM, Van Allen EM et al. A Phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest. New Drugs 32(1), 178–187 (2014).
  Medline CASGoogle Scholar
• 164. Chang T-C, Chen B-M, Lin W-W et al. Both IgM and IgG antibodies against polyethylene glycol can alter the biological activity of methoxy polyethylene glycol-epoetin beta in mice. Pharmaceutics 12(1), 15 (2019).
  Google Scholar
• 165. Hsieh YC, Wang HE, Lin WW et al. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes. Theranostics 8(11), 3164–3175 (2018).
  Medline CASGoogle Scholar
• 166. Yang Q, Jacobs TM, Mccallen JD et al. Analysis of pre-existing IgG and IgM antibodies against polyethylene glycol (PEG) in the general population. Anal. Chem. 88(23), 11804–11812 (2016).
  Medline CASGoogle Scholar
• 167. Kovacevic KD, Gilbert JC, Jilma B. Pharmacokinetics, pharmacodynamics and safety of aptamers. Adv. Drug Del. Rev. 134, 36–50 (2018).
  Medline CASGoogle Scholar
• 168. Moreno A, Pitoc GA, Ganson NJ et al. Anti-PEG antibodies inhibit the anticoagulant activity of PEGylated aptamers. Cell. Chem. Biol. 26(5), 634–644.e633 (2019).
  Medline CASGoogle Scholar
• 169. Ganson NJ, Povsic TJ, Sullenger BA et al. Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. J. Allergy Clin. Immunol. 137(5), 1610–1613.e1617 (2016).
  Medline CASGoogle Scholar
• 170. Povsic TJ, Lawrence MG, Lincoff AM et al. Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. J. Allergy Clin. Immunol. 138(6), 1712–1715 (2016).
  Medline CASGoogle Scholar
• 171. Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 13, 33–51 (2019).
  Medline CASGoogle Scholar
• 172. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Del. Rev. 60(12), 1421–1434 (2008).
  Medline CASGoogle Scholar
• 173. Han L, Gao Q, Zhou K et al. The Phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain. J. Clin. Oncol. 37(Suppl. 15), 2535–2535 (2019).
  Google Scholar
• 174. Saltarella I, Desantis V, Melaccio A et al. Mechanisms of resistance to Anti-CD38 daratumumab in multiple myeloma. Cells 9(1), 167 (2020).
  CASGoogle Scholar
• 175. Barroso J, Halder M, Whelan M. EURL ECVAM recommendation on non-animal-derived antibodies. Publications Office of the European Union. 1–74 (2020).
  Google Scholar
• 176. Avet-Loiseau H. Ultra high-risk myeloma. Hematology 2010(1), 489–493 (2010).
  MedlineGoogle Scholar
• 177. Jackson GH, Davies FE, Pawlyn C et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 20(1), 57–73 (2019).
  Medline CASGoogle Scholar
• 178. Fox TA, Horne GA, Craddock C et al. Trial re-investment to build better research for better impact. Lancet 394(10199), 635–636 (2019).
  MedlineGoogle Scholar
• 179. Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J. Hematol. Oncol. 8(1), 1–14 (2015).
  MedlineGoogle Scholar
• 180. Hoffmann P, Hofmeister R, Brischwein K et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int. J. Cancer 115(1), 98–104 (2005).
  Medline CASGoogle Scholar
• 181. Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy: figure 1. Cancer Res. 69(12), 4941–4944 (2009).
  Medline CASGoogle Scholar
• 182. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974–977 (2008).
  Medline CASGoogle Scholar
• 183. Ahamadi-Fesharaki R, Fateh A, Vaziri F et al. Single-chain variable fragment-based bispecific antibodies: hitting two targets with one sophisticated arrow. Mol. Ther. Oncolytics. 14, 38–56 (2019).
  Medline CASGoogle Scholar
• 184. Bruno J. Predicting the uncertain future of aptamer-based diagnostics and therapeutics. Molecules 20(4), 6866–6887 (2015).
  Medline CASGoogle Scholar
• 185. Norman RA, Ambrosetti F, Bonvin AMJJ et al. Computational approaches to therapeutic antibody design: established methods and emerging trends. Brief Bioinform. 21(5), 1549–1567 (2020). •• Useful background for understanding the application of computational methods to antibody-based therapeutics.
  MedlineGoogle Scholar
• 186. Bell DR, Weber JK, Yin W, Huynh T, Duan W, Zhou R. In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers. Proc. Natl Acad. Sci. USA. 117(15), 8486–8493 (2020).
  Medline CASGoogle Scholar
• 187. Rabal O, Pastor F, Villanueva H, Soldevilla MM, Hervas-Stubbs S, Oyarzabal J. In silico aptamer docking studies: from a retrospective validation to a prospective case study-TIM3 aptamers binding. Mol. Ther. Nucleic Acids 5(10), e376 (2016). •• Example of computational methods used to study aptamers.
  MedlineGoogle Scholar
• 188. Ahirwar R, Nahar S, Aggarwal S, Ramachandran S, Maiti S, Nahar P. In silico selection of an aptamer to estrogen receptor alpha using computational docking employing estrogen response elements as aptamer-alike molecules. Sci. Rep. 6(1), 21285 (2016).
  Medline CASGoogle Scholar
• 189. Casalini T. Not only in silico drug discovery: molecular modeling towards in silico drug delivery formulations. J. Control. Rel. 332, 390–417 (2021).
  Medline CASGoogle Scholar
• 190. Salo-Ahen OMH, Alanko I, Bhadane R et al. Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes 9(1), 71 (2020).
  Google Scholar